Cambrian Bio
New York, US · Delaware corporation · 7 known investors
Cambrian Biopharma develops medicines targeting metabolic pathways that decline with age, aiming to treat and eventually prevent chronic metabolic disease and extend healthspan. It operates a drug sourcing and development model that advances a portfolio of drug candidates across multiple pipeline programs.
BiotechHealthtechLongevityMedical Devices
Founders & leadership
JG
James G. PeyerCo-founder
JP
James PeyerCEO, Founder, Board Director
JP
James Peyer, PhDinFounder & CEO
MN
Mark NuttallinChief Business Officer
RT
Ruth Thieroff-EkerdtinChief Medical Officer
WD
William DeVaulExecutive
BD
Bill DeVaulinChief Legal Officer
Board
CA
Christian Angermayerin𝕏Chairman, Co-Founder, Board DirectorFounder and Chairman of the Board at atai Life Sciences
MS
CA
Christian AngermeyerBoard director
PF-modified.png)
Paul FarrBoard director
BS
Brenton SaundersBoard director
Investors · 7
Reported raises · per SEC filings
Form D private placements$272.2M disclosed across 5 rounds · 2019–2026
▶$123.8MraisedJul 2026 · 80 investors · BiotechnologyRule 506(c)
▶$123.8MraisedJul 2026 · 80 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- James PeyerExecutive Officer, Director
- Juliette HanExecutive Officer, Director
- Mark NuttallExecutive Officer
- Ruth Thieroff-EkerdtExecutive Officer
- William DeVaulExecutive Officer
- Christian AngermeyerDirector
- Maryanna SaenkoDirector
- Brenton L. SaundersDirector
- Paul FarrDirector
- Martin GunhagaDirector
- Lorin Van NulandDirector
- Offering amount
- $129.8M
- Amount sold
- $123.8M
- First sale
- Jun 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$23MraisedJan 2025 · 30 investors · PharmaceuticalsRule 506(b)
▶$23MraisedJan 2025 · 30 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Christian AngermayerDirector
- Maryanna SaenkoDirector
- Paul FarrDirector
- James G. PeyerExecutive Officer, Director
- Brenton SaundersDirector
- Offering amount
- $37.6M
- Amount sold
- $23M
- First sale
- Jun 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$92.2MraisedDec 2021 · 56 investors · PharmaceuticalsRule 506(b)
▶$92.2MraisedDec 2021 · 56 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Christian AngermayerDirector
- Maryanna SaenkoDirector
- James G. PeyerExecutive Officer, Director, Promoter
- Offering amount
- $100.8M
- Amount sold
- $92.2M
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$28.4MraisedMay 2021 · 30 investors · PharmaceuticalsRule 506(b)
▶$28.4MraisedMay 2021 · 30 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- James G. PeyerExecutive Officer, Director, Promoter
- Christian AngermeyerDirector
- Maryanna SaenkoDirector
- Offering amount
- $28.4M
- Amount sold
- $28.4M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$4.8MraisedJan 2020 · 5 investors · PharmaceuticalsRule 506(b)
▶$4.8MraisedJan 2020 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Christian AngermeyerDirector
- James G. PeyerExecutive Officer, Director, Promoter
- Offering amount
- $4.8M
- Amount sold
- $4.8M
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Cambrian Bio went on to found or lead other companies.
Competitors · 2
by search overlap
Bridgebio25 shared keywordsBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.
Bioworld20 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with Cambrian Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Cambrian Bio do?
- Cambrian Biopharma develops medicines targeting metabolic pathways that decline with age, aiming to treat and eventually prevent chronic metabolic disease and extend healthspan. It operates a drug sourcing and development model that advances a portfolio of drug candidates across multiple pipeline programs.
- Who founded Cambrian Bio?
- Cambrian Bio was founded by James G. Peyer, James Peyer, James Peyer, PhD.
- Who are Cambrian Bio's investors?
- Cambrian Bio's investors include Catalio Capital Management, LP, Future Ventures, Khosla Ventures, Korify Capital, Sprint Vc, Strawberry Creek Ventures, atai Life Sciences.
- How much funding has Cambrian Bio raised?
- Cambrian Bio has disclosed $272.2M raised across 5 rounds.
- Where is Cambrian Bio headquartered?
- Cambrian Bio is headquartered in New York, US.